resumo
Organometallic-cyclodextrin inclusion compounds were obtained by the treatment of molybdenocene dichloride (Cp2MoCl2) with the modified cyclodextrins (CDs) heptakis-2,3,6-tri-O-methyl-beta-CD (TRIMEB) and 2-hydroxypropyl-beta-CD (HP beta CD) in aqueous solution. The products were isolated by liophilisation and characterised in the solid-state by powder XRD, thermogravimetric analysis, Raman and FTIR spectroscopy, and C-13 CP MAS NMR spectroscopy. The results are consistent with inclusion of Cp2MoCl2, rather than hydrolysis products such as [Cp2Mo(H2O)X](+) (X = Cl, OH) or [Cp2Mo(H2O)(2)](2+). The pure non-included metallocene CP2MoCl2, and its inclusion compounds with unmodified beta-CD, TRIMEB and HP beta CD were screened for their potential antiproliferative and cytotoxic activity, in both human cancer and healthy cell lines. Inclusion in CD was found to enhance the cytotoxic effect of Cp2MoCl2, with the TRIMEB adduct displaying the highest anti-tumour activity, along with the lowest toxicity towards non-neoplastic cells. (c) 2005 Elsevier B.V. All rights reserved.
palavras-chave
AGENT MOLYBDOCENE DICHLORIDE; METALLOCENE ANTITUMOR AGENTS; TITANOCENE DICHLORIDE; PHARMACEUTICAL APPLICATIONS; COORDINATION CHEMISTRY; CONFORMATIONAL-ANALYSIS; NMR-SPECTRA; IN-VITRO; COMPLEXES; DRUG
categoria
Chemistry
autores
Braga, SS; Marques, MPM; Sousa, JB; Pillinger, M; Teixeira-Dias, JJC; Goncalves, IS
nossos autores
Isabel Maria de Sousa Gonçalves
Professor associado
José J.C. Teixeira Dias
Professor Catedrático